Supernus Pharmaceuticals Inc (SUPN) support and resistance · rev $661.8M
Supernus Pharmaceuticals Inc (SUPN) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page maps Supernus Pharmaceuticals Inc (SUPN) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported SUPN revenue for 2024-12-31 was $661.8M. Net income was $73.9M. Revenue was up 8.9% from 2023-12-31 to 2024-12-31. SUPN currently screens at market cap $2.53B.
SUPN currently screens at market cap $2.53B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new SUPN 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the SUPN quote page for the session range and the stock page for the full model.
Not investment advice.